Detection Composition

• US 20100151472A1
• Filed: 11/12/2009
• Published: 06/17/2010
• Est. Priority Date: 11/12/2008
• Status: Active Grant

• Current Assignee: Nodality Inc.
• Original Assignee: Nodality Inc.
• Inventors: McGarrigle, Phillip, Nolan, Garry
• Granted Patent: US 8,309,306 B2
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C07K 1/13 Labelling of peptides
• CPC Class Codes: C12Q 1/682 Signal amplification
• CPC Class Codes: C12Q 2525/155 incorporating/generating a new priming site
• CPC Class Codes: C12Q 2563/107 fluorescence
• CPC Class Codes: C12Q 2565/102 Multiple non-interacting labels

Abstract

The invention provides methods, kits, devices and compositions for detecting one or more target analytes. In some embodiments, the invention provides binding elements and labeling elements capable of being joined through a plurality of joining elements.

Claims

1. A composition comprising:

a binding element directed against an activatable element, wherein said binding element comprises a first joining element, wherein said first joining element comprises a first oligonucleotide attached to said binding element, and wherein said first oligonucleotide comprises a first complementary oligonucleotide region;

a second joining element comprising a second oligonucleotide, wherein said second oligonucleotide comprises a labeling element, and wherein said second oligonucleotide comprises a second complementary oligonucleotide region; and

a third joining element comprising a third oligonucleotide, wherein said third oligonucleotide comprises a third complementary oligonucleotide region and a fourth complementary oligonucleotide region, wherein said third complementary oligonucleotide region is complementary to said first complementary oligonucleotide region in said first joining element and wherein said fourth complementary oligonucleotide region is complementary to said second complementary oligonucleotide region in said second joining element.

3. The composition of claim 1 or 2 wherein said binding element is a peptide, a polypeptide, an oligopeptide, or an antibody.

4. The composition of claim 1 or 2 wherein said joining elements are independently selected from the group consisting of DNA, peptide nucleic acids, RNA, leucine zippers, polymers, or peptide loops.

5. The composition of claim 1 or 2 wherein more than one labeling elements are attached to said second joining element.

6. The composition of claim 1 or 2 wherein said labeling element is an element selected from the group consisting of small molecule fluorophores, proteinaceous fluorophores, radioisotopes, enzymes, antibodies, chemiluminescent molecules, biotin, streptavidin, digoxigenin, chromogenic dyes, luminescent dyes, phosphorous dyes, luciferase, magnetic particles, beta-galactosidase, amino groups, carboxy groups, maleimide groups, oxo groups and thiol groups, quantum dots, chelated or caged lanthanides, isotope tags, radiodense tags, electron-dense tags, radioactive isotopes, paramagnetic particles, agarose particles, mass tags, e-tags, nanoparticles, and vesicle tags.

7. The composition of claim 1 or 2 wherein the labeling element comprises an enzyme and precursor compound.

8. The composition of claim 1 or 2 wherein the joining element is an oligonucleotide or a nucleic acid having about 10 to about 100 bases in length.

9. The composition of claim 1 or 2 wherein said first joining element is covalently attached to said binding element.

10. The composition of claim 1 or 2 wherein said activatable element is a phosphoprotein.

2. A composition comprising:

a binding element directed against an activatable element, wherein said binding element comprises a first joining element, wherein said joining element comprises a first oligonucleotide attached to said binding element, and wherein said first oligonucleotide comprises a first complementary oligonucleotide region;

a second joining element comprising a second oligonucleotide, wherein said second oligonucleotide comprises a labeling element, and wherein said second oligonucleotide comprises a second complementary oligonucleotide region, wherein said second complementary oligonucleotide region is complementary to said first complementary oligonucleotide region is said first joining element.

11. A method for labeling a binding element comprising:

providing a binding element, wherein said binding element is directed against an activatable element;

providing a first joining element and a second joining element, wherein said first joining element comprises a first oligonucleotide, wherein said first oligonucleotide comprises a first complementary oligonucleotide region, wherein said second joining element comprises a second oligonucleotide, wherein said second oligonucleotide comprises a labeling element, wherein said second oligonucleotide comprises a second complementary oligonucleotide region, and wherein said second complementary oligonucleotide region in said second joining element is complementary to said first complementary oligonucleotide region in said first joining element;

attaching said first joining element to said binding element, and

hybridizing said second complementary region in second joining element to said first complementary region in said first joining element such that a complex is formed between said binding element, said first joining element and said second joining element.

12. (canceled)

13. (canceled)

14. A method of detecting the presence or absence of an activatable element in a sample comprising:

providing a sample potentially containing the activatable element;

providing a binding element, wherein said binding element is directed against said target activatable element;

wherein said binding element comprises a first joining element and a second joining element, wherein said first joining element comprises a first oligonucleotide attached to said binding element, wherein said first oligonucleotide comprises a first complementary oligonucleotide region, wherein said second joining element comprises a second oligonucleotide, wherein said second oligonucleotide comprises a labeling element, wherein said second oligonucleotide comprises a second complementary oligonucleotide region, wherein said second complementary oligonucleotide region in said second joining element is complementary to said first complementary oligonucleotide region in said first joining element; and

wherein said second complementary region in second joining element is hybridized to said first complementary region in said first joining element;

contacting said sample with said binding element; and

detecting said labeling element, wherein said labeling element is indicative of the presence or absence of the activatable element in the sample.

15-23. -23. (canceled)

24. A kit comprising:

(i) a binding element directed against an activatable element,

(ii) a first joining element, wherein said first oligonucleotide comprises a first complementary oligonucleotide region;

(iii) a second joining element comprising a second oligonucleotide, wherein said second oligonucleotide comprises a labeling element, and wherein said second oligonucleotide comprises a second complementary oligonucleotide region;

(iv) a third joining element comprising a third oligonucleotide, wherein said third oligonucleotide comprises a third complementary oligonucleotide region and a fourth complementary oligonucleotide region, wherein said third complementary oligonucleotide region is complementary to said first complementary oligonucleotide region in said first joining element and wherein said fourth complementary oligonucleotide region is complementary to said second complementary oligonucleotide region in said second joining element; and

(v) instructions to form a complex between said binding element, said first joining element, said second joining element and said third joining element.

25. A kit comprising:

(i) a binding element directed against an activatable element,

(ii) a first joining element, wherein said joining element comprises a first oligonucleotide, wherein said first oligonucleotide comprises a first complementary oligonucleotide region;

(iii) a second joining element comprising a second oligonucleotide, wherein said second oligonucleotide comprises a labeling element, and wherein said second oligonucleotide comprises a second complementary oligonucleotide region, wherein said second complementary oligonucleotide region is complementary to said first complementary oligonucleotide region in said first joining element; and

(iv) instructions to form a complex between said binding element, said first joining element, and said second joining element.

26-34. -34. (canceled)